Drug Approval | February 13, 2025
FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Increases speed to market for drug developers working on nucleic acid therapeutics
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Subscribe To Our Newsletter & Stay Updated
